Harmony Biosciences Holdings Inc (HRMY) concluded trading on Thursday at a closing price of $28.46, with 0.46 million shares of worth about $12.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.83% during that period and on April 17, 2025 the price saw a gain of about 1.86%. Currently the company’s common shares owned by public are about 57.14M shares, out of which, 43.54M shares are available for trading.
Stock saw a price change of -1.83% in past 5 days and over the past one month there was a price change of -17.27%. Year-to-date (YTD), HRMY shares are showing a performance of -17.29% which decreased to -4.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $26.47 but also hit the highest price of $41.61 during that period. The average intraday trading volume for Harmony Biosciences Holdings Inc shares is 710.12K. The stock is currently trading -8.06% below its 20-day simple moving average (SMA20), while that difference is down -14.97% for SMA50 and it goes to -18.11% lower than SMA200.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) currently have 57.14M outstanding shares and institutions hold larger chunk of about 83.42% of that.
The stock has a current market capitalization of $1.63B and its 3Y-monthly beta is at 0.86. PE ratio of stock for trailing 12 months is 11.34, while it has posted earnings per share of $2.51 in the same period. Its PEG reads 0.41 and has Quick Ratio of 3.27 while making debt-to-equity ratio of 0.35. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HRMY, volatility over the week remained 4.46% while standing at 4.73% over the month.
Stock’s fiscal year EPS is expected to rise by 25.17% while it is estimated to increase by 28.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on February 11, 2025 offering a Buy rating for the stock and assigned a target price of $55 to it. Coverage by H.C. Wainwright stated Harmony Biosciences Holdings Inc (HRMY) stock as a Buy in their note to investors on December 17, 2024, suggesting a price target of $75 for the stock. On October 10, 2024, Raymond James Resumed their recommendations, while on September 10, 2024, UBS Initiated their ratings for the stock with a price target of $56. Stock get a Buy rating from Citigroup on June 21, 2024.
